Current Ratio

CRISPR Therapeutics’ current ratio of 17.96x means the company has $17.96 in current assets (like cash and receivables) for every $1 of current liabilities due within a year—a measure of short-term financial health.

This ratio far exceeds the healthcare sector median of 2.06x, placing the company in the 98th percentile among its sector peers, indicating exceptionally strong liquidity relative to similar firms. The trend for this metric is not available, with both the year-over-year and quarter-over-quarter changes listed as N/A, so no directional insight can be drawn from historical movements. A very high current ratio suggests minimal short-term default risk, but without trend data it could also point to excess cash or inefficient use of assets, creating an ambiguous investment picture. This metric supports the overall NEUTRAL verdict: the extreme liquidity level reduces near-term risk, yet the lack of trend and potential for idle capital prevents a positive or negative tilt.

Frequently Asked Questions

Closest Sector Peers